[Impact of enterobacteriaceae-producing extended-spectrum beta-lactamases (ESBLE) incidence increasing on barrier precautions implementation in a university hospital]

Pathol Biol (Paris). 2013 Oct;61(5):217-22. doi: 10.1016/j.patbio.2012.06.001. Epub 2012 Jul 26.
[Article in French]

Abstract

Aim of the study: The French national surveillance program of multidrug-resistant bacteria (MDR) shows an increase of enterobacteriaceae-producing extended-spectrum beta-lactamases (ESBLE) incidence. The objectives of this study were to assess: the incidence of EBLSE in a large French university hospital between 2005 and 2010, and the difference of barrier precautions implementation between ESBL and other MDR.

Methods: The ESBLE incidence measure used data from the laboratory of bacteriology. The application of isolation and barrier precautions was analyzed from the MRB national surveillance data over a 3-year period from 2006 to 2008. Data were entered and analyzed using Epi Info software. The Chi(2) test was used for the comparison of proportions.

Results: The overall incidence of ESBLE was significantly higher in 2010 than in 2005 (0.20/1000 patients-days vs 0.03/1000 patients-days, respectively) (P<0.001). The same was observed for Escherichia coli incidence with rates ranging from 0.02/1000 patients-days in 2005 to 0.15/1000 patients-days in 2010. Isolation precautions for patients with EBLSE were applied in relation for most patients with MRB (ESBLE vs others), without significant difference.

Conclusion: The surveillance programme of MRB showed a significant increase of ESBLE, especially for E. coli. Isolation and barrier precautions were used for most patients with MRB, including ESBLE.

Keywords: Bactéries multirésistantes; Densités d’incidence; Enterobacteriaceae-producing extended-spectrum beta-lactamases; Entérobactéries productrices de bêta-lactamases à spectre étendu; Escherichia coli; Incidence; Isolation precautions; Multidrug-resistant bacteria; Précautions complémentaires.

Publication types

  • English Abstract

MeSH terms

  • Cross Infection / microbiology
  • Drug Resistance, Multiple*
  • Enterobacteriaceae / enzymology*
  • Enterobacteriaceae / isolation & purification
  • Enterobacteriaceae Infections / drug therapy
  • Enterobacteriaceae Infections / epidemiology*
  • Enterobacteriaceae Infections / microbiology*
  • Escherichia coli Infections / epidemiology
  • France / epidemiology
  • Hospitals, University*
  • Humans
  • Infection Control
  • Patient Isolation
  • beta-Lactamases / biosynthesis*

Substances

  • beta-Lactamases